NTLA Stock Crashes As Patent Decision Shadows CRISPR Gene-Editing Data – Investor's Business Daily
Business News
- NTLA Stock Crashes As Patent Decision Shadows CRISPR Gene-Editing Data Investor’s Business Daily
- Intellia now has the data for No. 1 unanswered gene editing question: Does it last? FierceBiotech
- Intellia’s first CRISPR gene editing therapy shows promise in small study The Boston Globe
- Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire
- Intellia and Regeneron update data for CRISPR candidate in ATTR amyloidosis Seeking Alpha
- View Full Coverage on Google News
Source: Business News